Category: United States
-
Federal Circuit partly grants Bayer second chance in defending rivaroxaban patent invalidation campaign
The Federal Circuit has partly affirmed and partly vacated a United States Patent and Trademark Office’s Patent Trial and Appeal Board decision that deemed one of Bayer’s rivaroxaban-related patents invalid, in a three-year case initiated by rivals Mylan Pharmaceuticals, Teva Pharmaceuticals, and Invagen Pharmaceuticals.
-
Headwater launches fresh cloud messaging patent infringement campaign: Tencent, Uber, Target, Walmart among defendants
The patent infringement campaign appears to be targeting Google customers, as the complaints all refer to the company’s Firebase Cloud Messaging, and it asserts a patent also involved in a recently-settled dispute with Samsung Electronics.
-
American Express handed win in loyalty program patent infringement dispute
A U.S. district court has granted a motion to dismiss a complaint filed by Loyal-T Systems LLC against American Express for failing to state a claim for relief.
-
Moderna, Alnylam settle U.S. COVID vaccine patent infringement dispute
Alnylam has settled its three-year dispute against Moderna in the District of Delaware, after a precedential Federal Circuit decision found the patentee had acted as its own lexicographer in defining a key patent specification term, foreclosing its infringement allegations.
-
Samsung, Headwater settle wireless patent dispute
Samsung and Headwater Research have settled a two-year patent infringement dispute.
-
Regeneron makes strides in global Eylea patent enforcement campaign: settles with Sandoz, files fresh UK suits
Regeneron has settled its year-long patent infringement dispute with Sandoz over several patents related to its eye disease drug Eylea, and filed a fresh lawsuit against two more rivals over the same drug in the High Court of Justice for England & Wales.
-
Pfizer, BioNTech hit back against GSK mRNA suits in UPC, Ireland: file UK revocation action
The move does not come as a major surprise, given the pharma companies’ previous success against GlaxoSmithKline in the UK.
-
Acer seeking counterleverage against Nokia through “threat letters” in U.S. despite highly asymmetric SEP portfolios and sales volumes: DJ action
Acer sent “threat letters” to U.S. telecommunications carriers using Nokia equipment, provoking a declaratory judgment complaint.
-
Oura escalates Ultrahuman patent dispute with more patents and accusations of editing Wikipedia page to accuse Oura of patent trolling
The patent dispute between smart-ring pioneer Oura and Ultrahuman is getting dirty, with Oura accusing Ultrahuman of having edited its Wikipedia page and impersonated its CEO.
-
Stanford retains cancer detection patents licensed to Foresight Diagnostics, but Roche gets non-exclusive license: settlement
Roche Molecular Systems, Stanford and Foresight Diagnostics have recently settled a dispute over trade secrets, breach of contract, unfair competition and patent ownership.